Results 61 to 70 of about 4,961 (248)
TH Open, 2019 Idarucizumab is a humanized antigen binding fragment (Fab) of a recombinant anti-dabigatran monoclonal antibody (IgG1-kappa) that allows rapid and sustained reversal of dabigatran-induced anticoagulation in case of bleeding or urgent surgery.
Nicolas Gendron +5 more
doaj +1 more source
Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolism [PDF]
, 2015 Objective To compare the safety and efficacy of dabigatran to warfarin for the treatment of deep vein thrombosis and pulmonary embolism. Background Venous thromboembolism (VTE) is a disease comprised of two conditions: deep vein thrombosis and pulmonary
Dixon, Dave L., Ogbonna, Kelechi C.
core +3 more sources
Trauma Case Reports, 2018 Introduction: Idarucizumab is the first effective humanized monoclonal antibody fragment developed specifically as a reversal agent for dabigatran, a Direct Oral Anticoagulant. Despite recent trials demonstrating reversal of clinically relevant bleeding,
Gail Edwards +3 more
doaj +1 more source
Real-world clinical practice of current periprocedural anticoagulation management in catheter ablation of atrial fibrillation: Data from a large prospective ablation registry. [PDF]
J ArrhythmAnticoagulation with direct thrombin inhibitors was a reasonable periprocedural anticoagulation regimen to reduce periprocedural complications in atrial fibrillation ablation. Abstract Background The guidelines recommend anticoagulation management with uninterrupted warfarin or direct thrombin inhibitors (DTIs) during the atrial fibrillation (AF ...
Taomoto Y +27 more
europepmc +2 more sources
Direkt orális antikoagulánsok a kardiológiában | Direct oral anticoagulants in cardiology [PDF]
, 2016 Absztrakt Az antithromboticus gyógyszeres kezelés napjaink gyakorlati medicinájának egyik fontos, de sokszor bizony eléggé faragatlan talpköve.
Kiss, Róbert Gábor
core +1 more source
New oral anticoagulants and their reversal agents [PDF]
, 2018 Atrial fibrillation is a commonly encountered pathology in medical practice, and its prevalence has shown a continuous rise over the past years. Atrial fibrillation has a significant impact on patients\u27 quality of life, not only due to the standard ...
Bodean, Oana +9 more
core +4 more sources
Frontiers in Neurology, 2019 We report a case of intravenous thrombolysis in acute ischemic stroke of anterior choroidal artery following the antagonization of dabigatran with idarucizumab.
Maren Hieber, Juergen Bardutzky
doaj +1 more source
Evidence supporting idarucizumab for the reversal of dabigatran [PDF]
The American Journal of Emergency Medicine, 2016 Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran. It has demonstrated prompt and durable reversal of the anticoagulant effects of dabigatran in animal studies and phase 1 studies of young, elderly, and renally impaired volunteers.
openaire +6 more sources
World Journal of Clinical Cases, 2022 BACKGROUND The drug instructions for dabigatran recommend adjusting the dosage to 110 mg twice daily for patients with bleeding risk, and performing at least one renal function test per year for patients with moderate renal impairment.
Yu Jia +7 more
semanticscholar +1 more source
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management [PDF]
, 2017 Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in the prevention of embolic stroke in non-valvular atrial fibrillation ...
Cheung, KS, Leung, WK
core +1 more source